Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary
Post# of 281
(Total Views: 217)
Posted On: 02/24/2020 2:29:59 PM
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media
- POAI subsidiary announces new media for growing ovarian tumors in lab
- Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers
- New media available as cell-culture market expected to reach $2.3 billion by 2024
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://nnw.fm/2bdtl). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers and precision therapies.
“Using these proprietary media, our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis President Richard Gabriel stated in a news release. “The resulting cells have a 95+% match to cells found in patient bodies.”
The timing of POAI’s announcement couldn’t be better. Experts predict that the global cell-culture media market will reach $2.3 billion by 2024. That growth – a steady 8.4% CAGR – is primarily fueled by the increased use of biological-based drugs such as immune therapies, a space where POAI and its subsidiaries are establishing themselves as both leaders and pioneers.
POAI anticipates that the new media will be available Q1 2020 through Massachusetts-based US Biological, a primary brand for the life-science industry. United States Biological’s biochemicals, antibodies, recombinant proteins, cell-culture media and molecular biology kits are used in virtually all scientific applications and settings including genomic research, biotechnology, pharmaceutical development and the diagnosis of disease.
Traditionally, cell-culture media selects for only one or two fast-growing cell types, so the ability to identify 25 different cell types is a significant advancement. The proprietary media developed by TumorGenesis are designed specifically to assist researchers in isolating and maintaining the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory.
“We believe by helping researchers develop cells and tumors that more closely mimic cells and tumors found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” said Gabriel. Acknowledging that specialty media comprises only a small subset of the market, Gabriel explained that TumorGenesis sees this initial ovarian-specific formulation as the first in what the company anticipates being a long line of tools and services it will offer to cancer researchers.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- POAI subsidiary announces new media for growing ovarian tumors in lab
- Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers
- New media available as cell-culture market expected to reach $2.3 billion by 2024
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://nnw.fm/2bdtl). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers and precision therapies.
“Using these proprietary media, our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis President Richard Gabriel stated in a news release. “The resulting cells have a 95+% match to cells found in patient bodies.”
The timing of POAI’s announcement couldn’t be better. Experts predict that the global cell-culture media market will reach $2.3 billion by 2024. That growth – a steady 8.4% CAGR – is primarily fueled by the increased use of biological-based drugs such as immune therapies, a space where POAI and its subsidiaries are establishing themselves as both leaders and pioneers.
POAI anticipates that the new media will be available Q1 2020 through Massachusetts-based US Biological, a primary brand for the life-science industry. United States Biological’s biochemicals, antibodies, recombinant proteins, cell-culture media and molecular biology kits are used in virtually all scientific applications and settings including genomic research, biotechnology, pharmaceutical development and the diagnosis of disease.
Traditionally, cell-culture media selects for only one or two fast-growing cell types, so the ability to identify 25 different cell types is a significant advancement. The proprietary media developed by TumorGenesis are designed specifically to assist researchers in isolating and maintaining the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory.
“We believe by helping researchers develop cells and tumors that more closely mimic cells and tumors found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” said Gabriel. Acknowledging that specialty media comprises only a small subset of the market, Gabriel explained that TumorGenesis sees this initial ovarian-specific formulation as the first in what the company anticipates being a long line of tools and services it will offer to cancer researchers.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)